Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
The latest update is out from Nasus Pharma Ltd. ( (NSRX) ).
On February 13, 2026, Nasus Pharma announced it had closed a $15 million private placement of ordinary shares and accompanying warrants, priced at a premium to its last NYSE American closing price. The financing, led by Citizens Capital Markets with Laidlaw & Company as co-placement agent, is expected to materially strengthen the company’s balance sheet and extend funding visibility.
Under the deal, investors purchased 2,695,425 ordinary shares and an equal number of warrants exercisable at $6.53 per share, which are immediately exercisable and will lapse no later than two years after issuance or 30 trading days after top-line NS002 pivotal data. Nasus plans to use the proceeds to advance NS002 into pivotal clinical development for anaphylaxis treatment, initiate first-in-human studies for other pipeline candidates based on its proprietary intranasal powder platform, and support working capital and general corporate needs.
The unregistered securities were sold in a U.S. private placement structure with resale registration rights, underscoring continued institutional investor interest in Nasus’s intranasal technology approach. For stakeholders, the transaction reduces near-term financing risk while sharpening the company’s focus on delivering pivotal data and a potential NDA submission for NS002, a key value inflection point in its strategy to validate its broader intranasal platform.
The most recent analyst rating on (NSRX) stock is a Buy with a $19.00 price target. To see the full list of analyst forecasts on Nasus Pharma Ltd. stock, see the NSRX Stock Forecast page.
More about Nasus Pharma Ltd.
Nasus Pharma Ltd. is a clinical-stage pharmaceutical company focused on developing powder-based intranasal therapies for acute medical conditions in community settings. Its lead candidate, NS002, is an intranasal powder epinephrine product being positioned as a needle-free alternative to traditional epinephrine autoinjectors for patients at risk of anaphylaxis.
Average Trading Volume: 6,085
Technical Sentiment Signal: Strong Sell
See more insights into NSRX stock on TipRanks’ Stock Analysis page.